PPARD and metabolic disease: More importantly, PPARβ/δ was relatively unaffected by aging[57].The actions of PPARβ/δ inskeletal muscle, that is, oxidative myofiber remodeling andincreaseof fatty acid burning capacity [60], may give hope to the specific agonists ofthisnuclearreceptor for therapeutic usefulness in the age-related metabolic diseases.